Related Experiment Video
Updated: Jul 16, 2026

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation
Published on: June 8, 2018
Synergistic Sensitization of Pancreatic Cancer Cells by Nanosecond Pulsed Electric Fields and Cold Atmospheric Plasma
Zobia Minhas1, Edwin A Oshin1,2, Lifang Yang3
1Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, VA 23508, USA.
Abstract:
Pancreatic cancer remains a highly lethal malignancy, with standard therapies offering limited benefits in advanced stages; thus, novel strategies that exploit specific cancer cell vulnerabilities are urgently needed. Building on our previous findings that nanosecond pulsed electric fields (nsPEF) combined with cold atmospheric plasma (CAP) produce enhanced cytotoxicity, this study investigates the molecular mechanisms underlying this synergy. Pan02 pancreatic cancer cells were subjected to nsPEF, CAP, or a combination of both. We assessed cell viability, reactive oxygen species (ROS) production, and mitochondrial integrity using metabolic assays, flow cytometry, and fluorescence microscopy. Apoptotic markers were evaluated via Western blotting and caspase activity assays. Combined nsPEF-CAP treatment significantly outperformed either modality alone in inducing cell death. Mechanistically, dual treatment triggered a surge in intracellular ROS, particularly mitochondrial superoxide, indicating severe oxidative stress. Distinct mitochondrial responses were observed: nsPEF reduced mitochondrial membrane potential, whereas CAP alone caused a slight elevation. Notably, while CAP induced apoptosis (evidenced by increased cleaved caspase-3 and caspase-3/7 activity), lethal nsPEF (100 pulses) caused cell death without triggering apoptotic signaling. However, mild nsPEF (20 pulses) significantly potentiated CAP-induced apoptosis. These findings suggest that nsPEF sensitizes cells to CAP treatment by amplifying oxidative stress and mitochondrial dysfunction. This synergistic combination represents a promising therapeutic approach for managing pancreatic cancer cells resistant to conventional therapies.
Insights
Combining nanosecond pulsed electric fields (nsPEF) and cold atmospheric plasma (CAP) shows promise for pancreatic cancer. This dual treatment enhances cancer cell death by increasing oxidative stress and mitochondrial dysfunction.
Area of Science:
- Biophysics
- Cancer Biology
- Biomedical Engineering
Background:
- Pancreatic cancer is a lethal malignancy with limited treatment options for advanced stages.
- Novel therapeutic strategies targeting cancer cell vulnerabilities are crucial.
- Previous research indicated enhanced cytotoxicity when combining nanosecond pulsed electric fields (nsPEF) and cold atmospheric plasma (CAP).
Purpose of the Study:
- To investigate the molecular mechanisms behind the synergistic cytotoxicity of combined nsPEF and CAP treatment on pancreatic cancer cells.
- To determine how nsPEF and CAP interact to induce cell death and explore their effects on reactive oxygen species (ROS) and mitochondrial function.
Main Methods:
- Pan02 pancreatic cancer cells were treated with nsPEF, CAP, or a combination of both.
- Cell viability was assessed using metabolic assays.
- ROS production, mitochondrial integrity, and apoptotic markers were evaluated using flow cytometry, fluorescence microscopy, Western blotting, and caspase activity assays.
Main Results:
- The combined nsPEF-CAP treatment demonstrated significantly higher cytotoxicity compared to either modality alone.
- Dual treatment led to a surge in intracellular ROS, particularly mitochondrial superoxide, indicating severe oxidative stress.
- Mild nsPEF potentiated CAP-induced apoptosis, while lethal nsPEF caused cell death independently of apoptotic signaling, suggesting nsPEF sensitizes cells to CAP.
Conclusions:
- The synergistic effect of nsPEF and CAP in pancreatic cancer treatment is mediated by amplified oxidative stress and mitochondrial dysfunction.
- This combination therapy presents a promising approach for overcoming resistance to conventional treatments in pancreatic cancer.
